In the LimeLight: Precision Bio appoints new CEO to replace founder

Editor’s Note: LimeLight is a new feature in WRAL TechWire providing another way to publish great news. Be sure to check out more LimeLight-worthy news at this link.

DURHAM – Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage biotechnology company using its ARCUS genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, announced Monday that Michael Amoroso was its new chief executive.

Michael Amoroso (Bio precision photo)

He will also become a member of the board of directors of Precision BioSciences, in each case effective October 15, 2021. Mr. Amoroso will succeed Matt Kane, co-founder, president and CEO, who is expected to serve as an advisor to the Company. to help ensure a smooth transition.

Mr. Amoroso is a biotechnology CEO with significant operational experience leading organizations focused on cell and gene therapy. He brings extensive experience leading teams in research, clinical development, regulatory and medical affairs, and commercial operations, with direct operational experience in the United States and major global markets, with a special emphasis on oncologic drugs, including CAR T cell therapies for hematologic malignancies.

“We are very pleased that Michael leads the Precision BioSciences team as we embark on the next phase of business growth and seek to maximize opportunities for our ARCUS platform,” said Kevin Buehler, Chairman of the Board of Directors of Precision BioSciences. “Michael’s deep commercial and operational expertise in hematology, oncology and gene therapy is an excellent choice for Precision and very relevant as we develop our late stage clinical development strategy and ultimately aim for commercialization. We believe Michael’s priorities and motivations fit well with the culture of Precision BioSciences and position him to successfully lead the Precision team as we pursue new treatments to defeat cancer and cure genetic diseases.

Mr. Amoroso is currently President and CEO of Abeona Therapeutics, Inc., a fully integrated gene and cell therapy company. Prior to this role, Mr. Amoroso was Commercial Director and COO of Abeona, responsible for overseeing the operational management of Abeona, including clinical research and development, regulation, medicine, commerce, corporate affairs and business development. Previously, Mr. Amoroso was Senior Vice President and Chief Commercial Officer of Kite Pharma, Inc. He held various executive positions at leading biopharmaceutical companies including Eisai Inc., Celgene Corporation, and began his biopharmaceutical career at Aventis (now Sanofi SA). Mr. Amoroso obtained his Executive MBA in Management from the Stern School of Business, New York University, and his BA in Biological Sciences, summa cum laude, from Rider University.

“I am delighted to join Precision BioSciences as the next President and CEO and to advance Precision’s new genome editing platform, ARCUS, in two leading areas of biotechnology, CAR allogeneic therapy. T and in vivo modification of genes. I look forward to working alongside Co-Founders Derek Jantz, Chief Scientific Officer and Jeff Smith, Chief Technology Officer, and the team at Precisioneers who are leading the development of our potentially breakthrough treatments with their persistence and continuous technical innovation. . I am particularly optimistic about the potential opportunity to bring new cell therapies to patients with hematologic malignancies, and about the prospects of filing three investigative new drug / clinical trial applications over the next three years for our gene editing treatments, ”commented Mr. Amoroso.

Mr. Buehler added, “Over the past 15 years, Matt has played a pivotal role in the formation, development and growth of Precision BioSciences. The Board of Directors sincerely thanks him for his commitment to the company and the significant accomplishments achieved by the Precision team under his leadership.

Source link

Comments are closed.